Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience

被引:3
|
作者
Michalak, Marcin [1 ]
Gasiorowska, Emilia [1 ]
Markwitz, Ewa Nowak [1 ]
机构
[1] Poznan Univ Med Sci, Dept Gynecol Oncol, PL-60535 Poznan, Poland
关键词
ovarian cancer; ROMA; HE4; CA; 125; EPIDIDYMIS PROTEIN 4; EPITHELIAL OVARIAN-CANCER; DIFFERENTIAL-DIAGNOSIS; MALIGNANCY ALGORITHM; TUMOR-MARKER; BENIGN; RISK; BIOMARKERS; SURVIVAL; DISCRIMINATION;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: The aim of this study was to compare and evaluate the quality of CA125, HE4, logistic regression model based on CA125 and HE4, and ROMA algorithm in preoperational differential diagnostics of the ovarian tumors. Material and methods: To the study 110 patients enrolled. Based on histopatological examination of removed tumors, they were divided into study group (56 cancer patients) and control one (nonmalignant 54 patients). Serum CA125 and HE4 concentrations were measured following a standard procedure. Results: A commonly accepted referential value for CA125 is 35 IU/ml. In our study, this cut-off value yielded very low sensitivity and specificity results (85.2% and 63.6%, respectively). When we adopted HE4 normal value to be 140 pM, the sensitivity and specificity obtained in the investigated population was 68.5% and 94.6%, respectively. When the cut-off value for HE4 was adopted as 74 pM, the sensitivity improved considerably (88.9%), but specificity decreased to 85.7%. In case of CA125 when we adopted Ca125 normal value to be 77 IU/ml, the sensitivity and specificity obtained in the investigated population was 81.5% and 83.6%, respectively. In analysis based on combination of biomarkers, the highest sensitivity was obtained for the logistic regression model based on CA125 and HE4 (89.5%). A little bit lower sensitivity was achieved for HE4 used as a single diagnostic test (88.9%). The highest specificity was observed for ROMA algorithm (94.5%). This means that ROMA algorithm is the best diagnostic tool to differentiate between the malignant and non-malignant ovarian tumors. Conclusions: 1. ROMA algorithm yielded the highest specificity and slightly lower sensitivity in the case of differential diagnosis between malignant and non-malignant ovarian tumors. Therefore, it should become a basic tool in the ovarian tumors diagnosis prior to a surgery. 2. HE4 as a single diagnostic test (based on one marker) was found to be better suited to the ovarian tumor differential diagnosis than CA125 test. 3. Combined test, based on double marker analysis, should be applied and then the risk of the ovarian cancer should be calculated. This approach is more effective than single marker analysis.
引用
收藏
页码:256 / 261
页数:6
相关论文
共 50 条
  • [41] Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence
    Wang, Qin
    Wu, Yuanyuan
    Zhang, Hao
    Yang, Kai
    Tong, Yang
    Chen, Liwen
    Zhou, Qiang
    Guan, Shihe
    CLINICAL LABORATORY, 2019, 65 (04) : 631 - 640
  • [42] THE UTILITY OF HE4, CA125 AND ROMA IN DIFFER ENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT GYNEACOLOGICAL DISEASES
    Escudero, J. M.
    Auge, J. M.
    Filella, X.
    Foj, L.
    Molina, R.
    TUMOR BIOLOGY, 2010, 31 : S58 - S59
  • [43] Retrospective evaluation of CA125, HE4 and ROMA index values in a consecutive population of 124 women
    Devey, A.
    Lukas, P.
    Cavalier, E.
    CLINICA CHIMICA ACTA, 2019, 493 : S134 - S134
  • [44] Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
    Carreras-Dieguez, Nuria
    Glickman, Ariel
    Munmany, Meritxell
    Casanovas, Georgina
    Agusti, Nuria
    Diaz-Feijoo, Berta
    Saco, Adela
    Sanchez, Beatriz
    Gaba, Lydia
    Angeles, Martina Aida
    Pahisa, Jaume
    Fernandez-Galan, Esther
    Torne, Aureli
    Fuste, Pere
    DIAGNOSTICS, 2022, 12 (01)
  • [45] A Survey on the Role of Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Ovarian Malignancy Algorithm (ROMA), and Risk of Malignancy Index (RMI) in Pelvic Mass
    Karimi-Zarchi, Mojgan
    Behtash, Nadereh
    Mousavi, Azamsadat
    Maghami, Fazemeh Ghaem
    Gilani, Mitra Moddares
    Chiti, Zohreh
    Barouti, Esmat
    Sheikhpour, Elnaz
    Javaheri, Atiyeh
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (12)
  • [46] Evaluation of CA125 and HE4 diagnostic performance in hereditary and sporadic ovarian cancer
    Tartaglione, S.
    Manganaro, L.
    Di Trani, M.
    Viggiani, V.
    Tomao, F.
    Angeloni, A.
    Anastasi, E.
    CLINICA CHIMICA ACTA, 2019, 493 : S158 - S159
  • [47] Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women
    Lu, Jie
    Zheng, Zhipeng
    Zhang, Qi
    Li, Guoli
    Li, Fengying
    Le, Zhian
    Huang, Jun
    Xie, Xinyou
    Zhang, Jun
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (05)
  • [48] CA125、HE4及ROMA指数对卵巢肿瘤的诊断价值
    李军
    南新营
    刘书磊
    贾军
    山西卫生健康职业学院学报, 2023, 33 (06) : 2 - 4
  • [49] THE DIAGNOSTIC CAPACITY OF HE4 AND CA 125 MEASURED ON THE ARCHITECT SYSTEM (ABBOTT DIAGNOSTICS)
    Lenhard, Miriam
    Burges, A.
    Hertlein, L.
    Kirschenhofer, A.
    Fuerst, S.
    Mayr, D.
    Nagel, D.
    Hofmann, K.
    Krocker, K.
    Stieber, P.
    TUMOR BIOLOGY, 2010, 31 : S112 - S112
  • [50] A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    Moore, Richard G.
    McMeekin, D. Scott
    Brown, Amy K.
    DiSilvestro, Paul
    Miller, M. Craig
    Allard, W. Jeffrey
    Gajewski, Walter
    Kurman, Robert
    Bast, Robert C., Jr.
    Skates, Steven J.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 40 - 46